SureNano Science Advances GLP-1 Candidate as Obesity Drug Market Grows
May 11th, 2026 2:11 PM
By: Newsworthy Staff
SureNano Science, through its subsidiary GlucaPharm, is advancing GEP-44, a triple agonist peptide for obesity and metabolic diseases, aiming to compete in a market projected to exceed $200 billion, while facing competition from major pharma companies like Eli Lilly and Novo Nordisk.
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) is making strides in the obesity drug market with its candidate GEP-44, a patented triple agonist peptide developed by subsidiary GlucaPharm Inc. The company is targeting improved efficacy, tolerability, and delivery flexibility as the global obesity and metabolic disease market expands rapidly. Long-term market projections exceed $200 billion, making this one of the most commercially significant therapeutic categories in modern healthcare.
SureNano enters an increasingly competitive landscape dominated by Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN), and Pfizer Inc. (NYSE: PFE). These large-cap incumbents currently hold the market with blockbuster GLP-1 products, but SureNano is positioning itself as an emerging microcap participant focused on preclinical innovation and alternative delivery technologies. The company’s approach includes broader platform opportunities that may extend beyond metabolic disease therapeutics.
Industry momentum is accelerating as major pharmaceutical companies advance next-generation obesity and diabetes therapies. New formulations, expanded indications, and reduced-frequency dosing strategies are aimed at improving patient access and adherence. SureNano’s GEP-44, a triple agonist targeting GLP-1 and peptide YY receptors, represents a differentiated approach in this growing field.
The company’s initial business involved the sale and distribution of the SureNano surfactant, a ready-to-mix food-grade compound for nanoemulsions. However, through the acquisition of GlucaPharm, SureNano is now developing into a pharmaceutical-focused company. The acquisition of GlucaPharm, announced in a press release dated February 23, 2026, positions SureNano to advance GEP-44, which has shown potential for non-injectable delivery and improved tolerability.
For more details on the press release, visit https://ibn.fm/g3EkQ. The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
